Pawel Janczyk

Pawel Janczyk currently serves as Lead Scientist at BridgeBio since November 2021, where the research focuses on the characterization of the novel oncogene AVIL crucial for various cancer types, including mechanisms of action and small-molecule drug screening. Previously, Pawel was a Postdoctoral Research Associate at the University of Virginia from June 2016 to November 2021 and had research experience as a Visiting Graduate Student Researcher in 2008. Early research experience also includes a trainee position at EMBL and a student trainee role at the Polish Academy of Sciences. Pawel holds a PhD in Biophysics from the University of Virginia and multiple degrees from the University of Gdansk, including MSc in Biotechnology and BSc degrees in Chemistry and Biotechnology.